DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Important Information on Fraudulent Emails to Practitioners
August 1, 2023

The Department of Health, Division of Medical Quality Assurance, is warning Florida health care practitioners about fraudulent emails that have been received by multiple licensees. Continue reading


New Legislation Impacting Your Profession
June 28, 2023

Click here to view a full list of bill summaries from the 2023 Florida Legislative Session that may impact your profession. Continue reading